We represented Laboratorios Sanfer (Invekra) and its shareholders (including General Atlantic), in the context of a primary and secondary sale of shares, subscribed and paid for by CDPQ, for an aggregate amount of  USD$500 million, evidencing approximately 24% of the capital stock of Invekra.